Global Anthrax Treatment Market - Industry Trends and Forecast to 2029

Description

List of Tables

Global anthrax treatment market is projected to register a CAGR of 6.6% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2021, the base year of calculation is 2022 and the forecast period is 2022 to 2029.

Market Segmentation:

Global Anthrax Treatment Market, By Type (Cutaneous Anthrax, Pulmonary Anthrax and Intestinal Anthrax), Route of Administration (Oral, Parenteral and Others), End User (Government Organization, Hospitals, Academic and Research Institutes, and Others), Country(U.S., Canada, Mexico, Germany, France, Italy, U.K., Spain, Netherlands, Russia, Switzerland, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, Luxembourg , Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific , Brazil, Argentina, Peru, Rest of South America, Saudi Arabia, South Africa, UAE, Israel, Kuwait, Egypt, Rest of Middle East and Africa) Industry Trends and Forecast to 2029.

Some of the major factors contributing to the growth of the anthrax treatment market are:

Rising prevalence of anthrax infections

Increasing research funding and the development of novel therapies for anthrax treatment

Market Players:

The key market players for global anthrax treatment market are listed below:

Alembic Pharmaceuticals

Integrated Bio Therapeutics Inc.

Sun Pharmaceutical Industries Ltd.

Zydus Group

Bayer AG

Pfizer Inc.

EMERGENT

Sanofi

Elusys Therapeutics

Porton Biopharma

Lupin, Soligenix

Takeda Pharmaceutical Company Limited

Teva Pharmaceutical Industries Ltd.

ARISTO Pharmaceuticals Private Limited

INDOCO REMEDIES LTD.

Paratek Pharmaceuticals, Inc.

DEINOVE

BlueWillow Biologics.

GC Biopharma, corp.

Altimmune

1 INTRODUCTION 75

1.1 OBJECTIVES OF THE STUDY 75
1.2 MARKET DEFINITION 75
1.3 OVERVIEW OF THE GLOBAL ANTHRAX TREATMENT MARKET 75
1.4 LIMITATIONS 77
1.5 MARKETS COVERED 77

2 MARKET SEGMENTATION 80

2.1 MARKETS COVERED 80
2.2 GEOGRAPHICAL SCOPE 81
2.3 YEARS CONSIDERED FOR THE STUDY 82
2.4 CURRENCY AND PRICING 82
2.5 DBMR TRIPOD DATA VALIDATION MODEL 83
2.6 MULTIVARIATE MODELLING 86
2.7 PRODUCT SEGMENT LIFELINE CURVE 86
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 87
2.9 DBMR MARKET POSITION GRID 88
2.10 MARKET APPLICATION COVERAGE GRID 89
2.11 VENDOR SHARE ANALYSIS 90
2.12 SECONDARY SOURCES 91
2.13 ASSUMPTIONS 91

3 EXECUTIVE SUMMARY 92

4 PREMIUM INSIGHTS 96

4.1 PESTEL ANALYSIS 98
4.2 PORTER'S FIVE FORCES 99
4.3 DEMOGRAPHIC TRENDS- 100
4.4 EPIDEMIOLOGY AND DEMOGRAPHICS- 102
- 4.4.1 INCIDENCE 102
- 4.4.2 DEVELOPED COUNTRIES- 102
- 4.4.3 DEVELOPING COUNTRIES- 102
4.5 PATIENT ENROLMENT STRATEGIES- 104
4.6 PATIENT FLOW DIAGRAM FOR ANTHRAX INFECTION- 108
4.7 CURRENT STATE OF ANTHRAX VACCINES 110
4.8 GLOBAL ANTIBIOTIC CONSUMPTION RATES INCREASED BY 46 PERCENT IN THE LAST TWO DECADES, ACCORDING TO THE FIRST STUDY TO PROVIDE LONGITUDINAL ESTIMATES FOR HUMAN ANTIBIOTIC CONSUMPTION COVERING 204 COUNTRIES FROM 2000 TO 2018. 114
4.9 GLOBAL ANTIBIOTIC CONSUMPTION AND PROJECTED CONSUMPTION- 115

5 THE M&A IN THE ANTHRAX MARKET INDICATES AN UPCOMING LONG RUN IN VACCINE DEVELOPMENT AROUND THE GLOBE. CURRENT AND SOME OF LAST YEAR'S ACQUISITION BETWEEN LEADERS AND SMALL SIZE PHARMACEUTICAL SHOWS THE CONTINUOUS DEVELOPMENT IN THE COMPANY'S PIPELINE FOR ANTHRAX TREATMENT. 119

6 GLOBAL ANTHRAX TREATMENT MARKET: REGULATIONS 121

7 MARKET OVERVIEW 125

7.1 DRIVERS 127
- 7.1.1 INCREASING INCIDENCE OF ANTHRAX INFECTION 127
- 7.1.2 INCREASE IN RESEARCH FUNDING AND THE DEVELOPMENT OF NOVEL THERAPIES FOR THE TREATMENT OF ANTHRAX 127
- 7.1.3 TECHNOLOGICAL ADVANCEMENTS IN TREATMENT PROCEDURE 128
- 7.1.4 STRATEGIC INITIATIVES ADOPTED BY MARKET PLAYERS 128
7.2 RESTRAINTS 129
- 7.2.1 HIGH COST ASSOCIATED WITH ANTHRAX DIAGNOSTIC TREATMENT 129
- 7.2.2 FALSE DATA INTERPRETATION 130
7.3 OPPORTUNITIES 130
- 7.3.1 RISING PRODUCT LAUNCHES 130
- 7.3.2 RISING GOVERNMENT INITIATIVES 131
- 7.3.3 IMPROVING A BETTER HEALTHCARE SYSTEM 131
7.4 CHALLENGES 132
- 7.4.1 LACK OF AWARENESS AMONG PEOPLE ABOUT ANTHRAX INFECTION 132
- 7.4.2 LACK OF SKILLED PROFESSIONALS 132

8 GLOBAL ANTHRAX TREATMENT MARKET, BY TYPE 134

8.1 OVERVIEW 135
8.2 CUTANEOUS ANTHRAX 138
- 8.2.1 ANTIBIOTICS 139
  - 8.2.1.1 BY DRUGS 139
    - 8.2.1.1.1 CIPROFLOXACIN 140
    - 8.2.1.1.2 LEVOFLOXACIN 140
    - 8.2.1.1.3 DOXYCYCLINE 140
    - 8.2.1.1.4 AMPICILLIN 140
    - 8.2.1.1.5 OTHERS 140
  - 8.2.1.2 BY PRODUCT TYPES 140
    - 8.2.1.2.1 GENERICS 140
    - 8.2.1.2.2 BRANDED 140
    - 8.2.1.2.2.1 CIPRO 141
    - 8.2.1.2.2.2 LEVO 141
    - 8.2.1.2.2.3 DOXY 141
    - 8.2.1.2.2.4 AMPICI 141
    - 8.2.1.2.2.5 OTHERS 141
- 8.2.2 ANTITOXINS 142
  - 8.2.2.1 RAXIBACUMAB 142
  - 8.2.2.2 OBILTOXAXIMAB (ANTHIM) 142
  - 8.2.2.3 ANTHRACIL (ANTHRAX IMMUNE GLOBULIN INTRAVENOUS) 142
  - 8.2.2.4 OTHERS 142
- 8.2.3 VACCINES 143
  - 8.2.3.1 RAXIBACUMAB 143
- 8.2.4 SURGERY 143
8.3 PULMONARY ANTHRAX 143
- 8.3.1 ANTIBIOTICS 144
  - 8.3.1.1 BY DRUGS 145
    - 8.3.1.1.1 CIPROFLOXACIN 145
    - 8.3.1.1.2 LEVOFLOXACIN 145
    - 8.3.1.1.3 DOXYCYCLINE 145
    - 8.3.1.1.4 AMPICILLIN 145
    - 8.3.1.1.5 OTHERS 145
  - 8.3.1.2 BY PRODUCT TYPES 146
    - 8.3.1.2.1 GENERICS 146
    - 8.3.1.2.2 BRANDED 146
    - 8.3.1.2.2.1 CIPRO 146
    - 8.3.1.2.2.2 LEVO 147
    - 8.3.1.2.2.3 DOXY 147
    - 8.3.1.2.2.4 AMPICI 147
    - 8.3.1.2.2.5 OTHERS 147
- 8.3.2 ANTITOXINS 147
  - 8.3.2.1 RAXIBACUMAB 147
  - 8.3.2.2 OBILTOXAXIMAB (ANTHIM) 147
  - 8.3.2.3 ANTHRACIL (ANTHRAX IMMUNE GLOBULIN INTRAVENOUS) 147
  - 8.3.2.4 OTHERS 148
- 8.3.3 VACCINES 148
  - 8.3.3.1 RAXIBACUMAB 148
  - 8.3.3.2 SURGERY 148
8.4 INTESTINAL ANTHRAX 148
- 8.4.1 ANTIBIOTICS 150
  - 8.4.1.1 BY DRUGS 150
    - 8.4.1.1.1 CIPROFLOXACIN 150
    - 8.4.1.1.2 LEVOFLOXACIN 150
    - 8.4.1.1.3 DOXYCYCLINE 150
    - 8.4.1.1.4 AMPICILLIN 151
    - 8.4.1.1.5 OTHERS 151
  - 8.4.1.2 BY PRODUCT TYPES 151
    - 8.4.1.2.1 GENERICS 151
    - 8.4.1.2.2 BRANDED 151
    - 8.4.1.2.2.1 CIPRO 152
    - 8.4.1.2.2.2 LEVO 152
    - 8.4.1.2.2.3 DOXY 152
    - 8.4.1.2.2.4 AMPICI 152
    - 8.4.1.2.2.5 OTHERS 152
- 8.4.2 ANTITOXINS 153
  - 8.4.2.1 RAXIBACUMAB 153
  - 8.4.2.2 OBILTOXAXIMAB (ANTHIM) 153
  - 8.4.2.3 ANTHRACIL (ANTHRAX IMMUNE GLOBULIN INTRAVENOUS) 153
  - 8.4.2.4 OTHERS 153
- 8.4.3 VACCINES 154
  - 8.4.3.1 RAXIBACUMAB 154
  - 8.4.3.2 SURGERY 154

9 GLOBAL ANTHRAX TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 155

9.1 OVERVIEW 156
9.2 PARENTERAL 159
9.3 ORAL 159
9.4 OTHERS 160

10 GLOBAL ANTHRAX TREATMENT MARKET, BY END USER 161

10.1 OVERVIEW 162
10.2 GOVERNMENT ORGANIZATION 165
10.3 HOSPITALS 165
10.4 ACADEMIC AND RESEARCH 166
10.5 OTHERS 168

11 GLOBAL VIRTUAL REALITY MARKET, BY GEOGRAPHY 169

11.1 GLOBAL 170
11.2 NORTH AMERICA 175
- 11.2.1 U.S. 192
- 11.2.2 CANADA 202
- 11.2.3 MEXICO 212
11.3 MIDDLE EAST AND AFRICA 222
- 11.3.1 SOUTH AFRICA 239
- 11.3.2 SAUDI ARABIA 248
- 11.3.3 UAE 257
- 11.3.4 EGYPT 266
- 11.3.5 ISRAEL 275
- 11.3.6 REST OF MIDDLE EAST AND AFRICA 284
11.4 EUROPE 285
- 11.4.1 GERMANY 301
- 11.4.2 FRANCE 312
- 11.4.3 U.K. 322
- 11.4.4 ITALY 333
- 11.4.5 RUSSIA 344
- 11.4.6 SPAIN 354
- 11.4.7 TURKEY 364
- 11.4.8 NETHERLANDS 374
- 11.4.9 SWITZERLAND 385
- 11.4.10 BELGIUM 396
- 11.4.11 REST OF EUROPE 407
11.5 ASIA-PACIFIC 408
- 11.5.1 CHINA 424
- 11.5.2 JAPAN 435
- 11.5.3 SOUTH KOREA 446
- 11.5.4 INDIA 457
- 11.5.5 AUSTRALIA 468
- 11.5.6 SINGAPORE 479
- 11.5.7 THAILAND 490
- 11.5.8 MALAYSIA 501
- 11.5.9 INDONESIA 512
- 11.5.10 PHILIPPINES 522
- 11.5.11 REST OF ASIA-PACIFIC 533
11.6 SOUTH AMERICA 534
- 11.6.1 BRAZIL 549
- 11.6.2 ARGENTINA 560
- 11.6.3 REST OF SOUTH AMERICA 571

12 GLOBAL ANTHRAX TREATMENT MARKET, COMPANY LANDSCAPE 572

12.1 COMPANY SHARE ANALYSIS: GLOBAL 572
12.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 573
12.3 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA 574
12.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 575

13 SWOT ANALYSIS 576

14 COMPANY PROFILE 577

14.1 BAYER AG 577
- 14.1.1 COMPANY SNAPSHOT 577
- 14.1.2 REVENUE ANALYSIS 577
- 14.1.3 COMPANY SHARE ANALYSIS 578
- 14.1.4 PRODUCT PORTFOLIO 578
- 14.1.5 RECENT DEVELOPMENTS 578
14.2 PFIZER INC. 579
- 14.2.1 COMPANY SNAPSHOT 579
- 14.2.2 REVENUE ANALYSIS 579
- 14.2.3 COMPANY SHARE ANALYSIS 580
- 14.2.4 PRODUCT PORTFOLIO 580
- 14.2.5 RECENT DEVELOPMENTS 580
14.3 TEVA PHARMACEUTICAL INDUSTRIES LTD 581
- 14.3.1 COMPANY SNAPSHOT 581
- 14.3.2 REVENUE ANALYSIS 581
- 14.3.3 COMPANY SHARE ANALYSIS 582
- 14.3.4 PRODUCT PORTFOLIO 582
- 14.3.5 RECENT DEVELOPMENT 582
14.4 SANOFI 583
- 14.4.1 COMPANY SNAPSHOT 583
- 14.4.2 REVENUE ANALYSIS 583
- 14.4.3 COMPANY SHARE ANALYSIS 584
- 14.4.4 PRODUCT PORTFOLIO 584
- 14.4.5 RECENT DEVELOPMENTS 584
14.5 TAKEDA PHARMACEUTICAL COMPANY LIMITED. 585
- 14.5.1 COMPANY SNAPSHOT 585
- 14.5.2 REVENUE ANALYSIS 585
- 14.5.3 PRODUCT PORTFOLIO 586
- 14.5.4 RECENT DEVELOPMENT 586
14.6 ALEMBIC PHARMACEUTICALS LIMITED 587
- 14.6.1 COMPANY SNAPSHOT 587
- 14.6.2 PRODUCT PORTFOLIO 587
- 14.6.3 RECENT DEVELOPMENTS 587
14.7 ALTIMMUNE 588
- 14.7.1 COMPANY SNAPSHOT 588
- 14.7.2 REVENUE ANALYSIS 588
- 14.7.3 PRODUCT PORTFOLIO 589
- 14.7.4 RECENT DEVELOPMENTS 589
14.8 ARISTO PHARMACEUTICALS PRIVATE LIMITED 590
- 14.8.1 COMPANY SNAPSHOT 590
- 14.8.2 PRODUCT PORTFOLIO 590
- 14.8.3 RECENT DEVELOPMENTS 590
14.9 BLUEWILLOW BIOLOGICS. 591
- 14.9.1 COMPANY SNAPSHOT 591
- 14.9.2 PRODUCT PORTFOLIO 591
- 14.9.3 RECENT DEVELOPMENTS 591
14.10 DEINOVE 592
- 14.10.1 COMPANY SNAPSHOT 592
- 14.10.2 REVENUE ANALYSIS 592
- 14.10.3 PRODUCT PORTFOLIO 593
- 14.10.4 RECENT DEVELOPMENTS 593
14.11 EMERGENT 594
- 14.11.1 COMPANY SNAPSHOT 594
- 14.11.2 REVENUE ANALYSIS 594
- 14.11.3 PRODUCT PORTFOLIO 595
- 14.11.4 RECENT DEVELOPMENTS 595
14.12 ELUSYS THERAPEUTICS INC. 596
- 14.12.1 COMPANY SNAPSHOT 596
- 14.12.2 PRODUCT PORTFOLIO 596
- 14.12.3 RECENT DEVELOPMENTS 596
14.13 GC BIOPHARMA CORP. 597
- 14.13.1 COMPANY SNAPSHOT 597
- 14.13.2 REVENUE ANALYSIS 597
- 14.13.3 PRODUCT PORTFOLIO 598
- 14.13.4 RECENT DEVELOPMENTS 598

14.14 INDOCO REMEDIES LTD. 599
- 14.14.1 COMPANY SNAPSHOT 599
- 14.14.2 REVENUE ANALYSIS 599
- 14.14.3 PRODUCT PORTFOLIO 600
- 14.14.4 RECENT DEVELOPMENTS 600
14.15 INTEGRATED BIOTHERAPEUTICS, INC. 601
- 14.15.1 COMPANY SNAPSHOT 601
- 14.15.2 PRODUCT PORTFOLIO 601
- 14.15.3 RECENT DEVELOPMENTS 601
14.16 LUPIN. 602
- 14.16.1 COMPANY SNAPSHOT 602
- 14.16.2 REVENUE ANALYSIS 602
- 14.16.3 PRODUCT PORTFOLIO 603
- 14.16.4 RECENT DEVELOPMENTS 603
14.17 PARATEK PHARMACEUTICALS, INC. 604
- 14.17.1 COMPANY SNAPSHOT 604
- 14.17.2 REVENUE ANALYSIS 604
- 14.17.3 PRODUCT PORTFOLIO 605
- 14.17.4 RECENT DEVELOPMENTS 605
14.18 PORTON BIOPHARMA 606
- 14.18.1 COMPANY SNAPSHOT 606
- 14.18.2 PRODUCT PORTFOLIO 606
- 14.18.3 RECENT DEVELOPMENTS 606
14.19 SOLIGENIX 607
- 14.19.1 COMPANY SNAPSHOT 607
- 14.19.2 REVENUE ANALYSIS 607
- 14.19.3 PRODUCT PORTFOLIO 608
- 14.19.4 RECENT DEVELOPMENTS 608
14.20 SUN PHARMACEUTICAL INDUSTRIES LTD. 609
- 14.20.1 COMPANY SNAPSHOT 609
- 14.20.2 REVENUE ANALYSIS 609
- 14.20.3 PRODUCT PORTFOLIO 610
- 14.20.4 RECENT DEVELOPMENTS 610
14.21 ZYDUS GROUP 611
- 14.21.1 COMPANY SNAPSHOT 611
- 14.21.2 REVENUE ANALYSIS 611
- 14.21.3 PRODUCT PORTFOLIO 612
- 14.21.4 RECENT DEVELOPMENTS 612

15 QUESTIONNAIRE 613

16 RELATED REPORTS 615

LIST OF TABLES

TABLE 1 POPULATION AT RISK (IN MILLIONS) BY REGION, LAND USE AND OCCUPATIONAL EXPOSURE, 2020- 101
TABLE 2 VACCINES IN DEVELOPMENT 110
TABLE 3 ANTIBIOTIC CONSUMPTION ESTIMATES BY GBD SUPER-REGION AND GBD REGION, FOR THE YEAR 2018- 117
TABLE 4 COUNTRY DATA OF ANTIBIOTICS CONSUMPTION- 118
TABLE 5 RECENT M&A IN ANTHRAX MARKET- 119
TABLE 6 ANTIBIOTICS MEDICINES 122
TABLE 7 FDA REQUIRES THE FOLLOWING SCENARIO BEFORE A DRUG IS APPROVED 124
TABLE 8 GLOBAL ANTHRAX TREATMENT MARKET, TYPE, 2020-2029 (USD MILLION) 137
TABLE 9 GLOBAL CUTANEOUS ANTHRAX IN ANTHRAX TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 138
TABLE 10 GLOBAL CUTANEOUS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 139
TABLE 11 GLOBAL ANTIBIOTICS IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 139
TABLE 12 GLOBAL BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 139
TABLE 13 GLOBAL BY PRODUCT TYPES ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 140
TABLE 14 GLOBAL BRANDED IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 141
TABLE 15 GLOBAL ANTITOXIN IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 142
TABLE 16 GLOBAL VACCINES IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 143
TABLE 17 GLOBAL PULMONARY ANTHRAX IN ANTHRAX TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 144
TABLE 18 GLOBAL PULMONARY ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 144
TABLE 19 GLOBAL ANTIBIOTICS IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 144
TABLE 20 GLOBAL BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 145
TABLE 21 GLOBAL BY PRODUCT TYPES ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 146
TABLE 22 GLOBAL BRANDED IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 146
TABLE 23 GLOBAL ANTITOXIN IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 147
TABLE 24 GLOBAL VACCINES IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 148
TABLE 25 GLOBAL INTESTINAL ANTHRAX IN ANTHRAX TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 149
TABLE 26 GLOBAL INTESTINAL ANTHRAX IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 149
TABLE 27 GLOBAL ANTIBIOTICS IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 150
TABLE 28 GLOBAL BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 150
TABLE 29 GLOBAL BY PRODUCT TYPES ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 151
TABLE 30 GLOBAL BRANDED IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 152
TABLE 31 GLOBAL ANTITOXIN IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 153
TABLE 32 GLOBAL VACCINES IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 154
TABLE 33 GLOBAL ANTHRAX TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 158
TABLE 34 GLOBAL PARENTERAL IN ANTHRAX TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 159
TABLE 35 GLOBAL ORAL IN ANTHRAX TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 160
TABLE 36 GLOBAL OTHERS IN ANTHRAX TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 160
TABLE 37 GLOBAL ANTHRAX TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION) 164
TABLE 38 GLOBAL GOVERNMENT ORGANIZATION IN ANTHRAX TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 165
TABLE 39 GLOBAL HOSPITALS IN ANTHRAX TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 166
TABLE 40 GLOBAL ACADEMIC AND RESEARCH IN ANTHRAX TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 167
TABLE 41 GLOBAL OTHERS IN ANTHRAX TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 168
TABLE 42 GLOBAL ANTHRAX TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 174
TABLE 43 NORTH AMERICA ANTHRAX TREATMENT MARKET, BY COUNTRY, 2020-2029 (USD MILLION) 179
TABLE 44 NORTH AMERICA ANTHRAX TREATMENT MARKET, BY TYPE , 2020-2029 (USD MILLION) 179
TABLE 45 NORTH AMERICA CUTANEOUS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 179
TABLE 46 NORTH AMERICA ANTIBIOTIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 179
TABLE 47 NORTH AMERICA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 180
TABLE 48 NORTH AMERICA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS) 180
TABLE 49 NORTH AMERICA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (ASP) 180
TABLE 50 NORTH AMERICA BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 181
TABLE 51 NORTH AMERICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 181
TABLE 52 NORTH AMERICA BRANDED IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS) 181
TABLE 53 NORTH AMERICA BRANDED TYPES ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (ASP) 181
TABLE 54 NORTH AMERICA ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 182
TABLE 55 NORTH AMERICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS) 182
TABLE 56 NORTH AMERICA BRANDED TYPES ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (ASP) 182
TABLE 57 NORTH AMERICA VACCINE IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 183
TABLE 58 NORTH AMERICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS) 183
TABLE 59 NORTH AMERICA BRANDED TYPES ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (ASP) 183
TABLE 60 NORTH AMERICA PULMONARY ANTHRAX IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 183
TABLE 61 NORTH AMERICA ANTIBIOTIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 183
TABLE 62 NORTH AMERICA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 184
TABLE 63 NORTH AMERICA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS) 184
TABLE 64 NORTH AMERICA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (ASP) 184
TABLE 65 NORTH AMERICA BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 184
TABLE 66 NORTH AMERICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 185
TABLE 67 NORTH AMERICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS) 185
TABLE 68 NORTH AMERICA BRANDED TYPES ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (ASP) 185
TABLE 69 NORTH AMERICA ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 186
TABLE 70 NORTH AMERICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS) 186
TABLE 71 NORTH AMERICA BRANDED TYPES ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (ASP) 186
TABLE 72 NORTH AMERICA VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 187
TABLE 73 NORTH AMERICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS) 187
TABLE 74 NORTH AMERICA BRANDED TYPES ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (ASP) 187
TABLE 75 NORTH AMERICA INTESTINAL ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 187
TABLE 76 NORTH AMERICA ANTIBIOTIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 187
TABLE 77 NORTH AMERICA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 188
TABLE 78 NORTH AMERICA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS) 188
TABLE 79 NORTH AMERICA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (ASP) 188
TABLE 80 NORTH AMERICA BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 188
TABLE 81 NORTH AMERICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 189
TABLE 82 NORTH AMERICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS) 189
TABLE 83 NORTH AMERICA BRANDED TYPES ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (ASP) 189
TABLE 84 NORTH AMERICA ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 190
TABLE 85 NORTH AMERICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 190
TABLE 86 NORTH AMERICA BRANDED TYPES ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (ASP) 190
TABLE 87 NORTH AMERICA VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 191
TABLE 88 NORTH AMERICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS) 191
TABLE 89 NORTH AMERICA BRANDED TYPES ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (ASP) 191
TABLE 90 NORTH AMERICA ANTHRAX TREATMENT MARKET, BY ROUTE OF ADMINISTRATIONS, 2020- 2029 (USD MILLION) 191
TABLE 91 NORTH AMERICA ANTHRAX TREATMENT MARKET, BY END USER, 2020- 2029 (USD MILLION) 191
TABLE 92 U.S. ANTHRAX TREATMENT MARKET, BY TYPE , 2020-2029 (USD MILLION) 192
TABLE 93 U.S. CUTANEOUS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 192
TABLE 94 U.S. ANTIBIOTIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 192
TABLE 95 U.S. BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 192
TABLE 96 U.S. BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS) 193
TABLE 97 U.S. BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 193
TABLE 98 U.S. BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 193
TABLE 99 U.S. BRANDED IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS) 194
TABLE 100 U.S. ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 194
TABLE 101 U.S. BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS) 194
TABLE 102 U.S. VACCINE IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 194
TABLE 103 U.S. BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 194
TABLE 104 U.S. PULMONARY ANTHRAX IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 195
TABLE 105 U.S. ANTIBIOTIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 196
TABLE 106 U.S. BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 196
TABLE 107 U.S. BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS) 196
TABLE 108 U.S. BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 196
TABLE 109 U.S. BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 197
TABLE 110 U.S. BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS) 197
TABLE 111 U.S. ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 197
TABLE 112 U.S. BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS) 197
TABLE 113 U.S. VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 198
TABLE 114 U.S. BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS) 198
TABLE 115 U.S. INTESTINAL ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 198
TABLE 116 U.S. ANTIBIOTIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 198
TABLE 117 U.S. BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 198
TABLE 118 U.S. BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS) 199
TABLE 119 U.S. BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 199
TABLE 120 U.S. BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 199
TABLE 121 U.S. BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS) 200
TABLE 122 U.S. ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 200
TABLE 123 U.S. BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 201
TABLE 124 U.S. VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 201
TABLE 125 U.S. BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS) 201
TABLE 126 U.S. ANTHRAX TREATMENT MARKET, BY ROUTE OF ADMINISTRATIONS, 2020- 2029 (USD MILLION) 201
TABLE 127 U.S. ANTHRAX TREATMENT MARKET, BY END USER, 2020- 2029 (USD MILLION) 201
TABLE 128 CANADA ANTHRAX TREATMENT MARKET, BY TYPE , 2020-2029 (USD MILLION) 202
TABLE 129 CANADA CUTANEOUS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 202
TABLE 130 CANADA ANTIBIOTIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 202
TABLE 131 CANADA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 202
TABLE 132 CANADA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS) 203
TABLE 133 CANADA BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 203
TABLE 134 CANADA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 203
TABLE 135 CANADA BRANDED IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS) 204
TABLE 136 CANADA ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 204
TABLE 137 CANADA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS) 204
TABLE 138 CANADA VACCINE IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 204
TABLE 139 CANADA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 205
TABLE 140 CANADA PULMONARY ANTHRAX IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 205
TABLE 141 CANADA ANTIBIOTIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 205
TABLE 142 CANADA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 205
TABLE 143 CANADA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS) 205
TABLE 144 CANADA BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 206
TABLE 145 CANADA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 206
TABLE 146 CANADA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS) 206
TABLE 147 CANADA ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 207
TABLE 148 CANADA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS) 207
TABLE 149 CANADA VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 207
TABLE 150 CANADA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS) 208
TABLE 151 CANADA INTESTINAL ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 208
TABLE 152 CANADA ANTIBIOTIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 208
TABLE 153 CANADA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 208
TABLE 154 CANADA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS) 209
TABLE 155 CANADA BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 209
TABLE 156 CANADA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 209
TABLE 157 CANADA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS) 210
TABLE 158 CANADA ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 210
TABLE 159 CANADA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 210
TABLE 160 CANADA VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 210
TABLE 161 CANADA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS) 210
TABLE 162 CANADA ANTHRAX TREATMENT MARKET, BY ROUTE OF ADMINISTRATIONS, 2020- 2029 (USD MILLION) 211
TABLE 163 CANADA ANTHRAX TREATMENT MARKET, BY END USER, 2020- 2029 (USD MILLION) 211
TABLE 164 MEXICO ANTHRAX TREATMENT MARKET, BY TYPE , 2020-2029 (USD MILLION) 212
TABLE 165 MEXICO CUTANEOUS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 212
TABLE 166 MEXICO ANTIBIOTIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 212
TABLE 167 MEXICO BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 212
TABLE 168 MEXICO BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS) 213
TABLE 169 MEXICO BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 213
TABLE 170 MEXICO BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 213
TABLE 171 MEXICO BRANDED IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS) 213
TABLE 172 MEXICO ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 214
TABLE 173 MEXICO BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS) 214
TABLE 174 MEXICO VACCINE IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 214
TABLE 175 MEXICO BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 214
TABLE 176 MEXICO PULMONARY ANTHRAX IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 214
TABLE 177 MEXICO ANTIBIOTIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 215
TABLE 178 MEXICO BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 215
TABLE 179 MEXICO BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS) 215
TABLE 180 MEXICO BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 216
TABLE 181 MEXICO BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 216
TABLE 182 MEXICO BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS) 216
TABLE 183 MEXICO ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 217
TABLE 184 MEXICO BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS) 217
TABLE 185 MEXICO VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 217
TABLE 186 MEXICO BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS) 218
TABLE 187 MEXICO INTESTINAL ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 218
TABLE 188 MEXICO ANTIBIOTIC ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 218
TABLE 189 MEXICO BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 218
TABLE 190 MEXICO BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS) 219
TABLE 191 MEXICO BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 219
TABLE 192 MEXICO BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 219
TABLE 193 MEXICO BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS) 219
TABLE 194 MEXICO ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 220
TABLE 195 MEXICO BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 220
TABLE 196 MEXICO VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (USD MILLION) 220
TABLE 197 MEXICO BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020- 2029 (UNITS) 220
TABLE 198 MEXICO ANTHRAX TREATMENT MARKET, BY ROUTE OF ADMINISTRATIONS, 2020- 2029 (USD MILLION) 220
TABLE 199 MEXICO ANTHRAX TREATMENT MARKET, BY END USER, 2020- 2029 (USD MILLION) 221
TABLE 200 MIDDLE EAST AND AFRICA ANTHRAX TREATMENT MARKET, BY COUNTRY, 2020-2029 (USD MILLION) 226
TABLE 201 MIDDLE EAST AND AFRICA ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 226
TABLE 202 MIDDLE EAST AND AFRICA CUTANEOUS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 226
TABLE 203 MIDDLE EAST AND AFRICA ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 227
TABLE 204 MIDDLE EAST AND AFRICA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 227
TABLE 205 MIDDLE EAST AND AFRICA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS) 227
TABLE 206 MIDDLE EAST AND AFRICA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (ASP) 227
TABLE 207 MIDDLE EAST AND AFRICA BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 228
TABLE 208 MIDDLE EAST AND AFRICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 228
TABLE 209 MIDDLE EAST AND AFRICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS) 228
TABLE 210 MIDDLE EAST AND AFRICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS) 228
TABLE 211 MIDDLE EAST AND AFRICA ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 229
TABLE 212 MIDDLE EAST AND AFRICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS) 229
TABLE 213 MIDDLE EAST AND AFRICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (ASP) 229
TABLE 214 MIDDLE EAST AND AFRICA VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 230
TABLE 215 MIDDLE EAST AND AFRICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS) 230
TABLE 216 MIDDLE EAST AND AFRICA BRANDED TYPES ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (ASP) 230
TABLE 217 MIDDLE EAST AND AFRICA PULMONARY ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 230
TABLE 218 MIDDLE EAST AND AFRICA ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 230
TABLE 219 MIDDLE EAST AND AFRICA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 231
TABLE 220 MIDDLE EAST AND AFRICA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS) 231
TABLE 221 MIDDLE EAST AND AFRICA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (ASP) 231
TABLE 222 MIDDLE EAST AND AFRICA BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 231
TABLE 223 MIDDLE EAST AND AFRICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 232
TABLE 224 MIDDLE EAST AND AFRICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS) 232
TABLE 225 MIDDLE EAST AND AFRICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS) 232
TABLE 226 MIDDLE EAST AND AFRICA ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 233
TABLE 227 MIDDLE EAST AND AFRICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS) 233
TABLE 228 MIDDLE EAST AND AFRICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (ASP) 233
TABLE 229 MIDDLE EAST AND AFRICA VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 233
TABLE 230 MIDDLE EAST AND AFRICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS) 234
TABLE 231 MIDDLE EAST AND AFRICA BRANDED TYPES ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (ASP) 234
TABLE 232 MIDDLE EAST AND AFRICA INTESTINAL ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 234
TABLE 233 MIDDLE EAST AND AFRICA ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 234
TABLE 234 MIDDLE EAST AND AFRICA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 235
TABLE 235 MIDDLE EAST AND AFRICA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS) 235
TABLE 236 MIDDLE EAST AND AFRICA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (ASP) 235
TABLE 237 MIDDLE EAST AND AFRICA BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 235
TABLE 238 MIDDLE EAST AND AFRICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 236
TABLE 239 MIDDLE EAST AND AFRICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS) 236
TABLE 240 MIDDLE EAST AND AFRICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS) 236
TABLE 241 MIDDLE EAST AND AFRICA ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 237
TABLE 242 MIDDLE EAST AND AFRICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS) 237
TABLE 243 MIDDLE EAST AND AFRICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (ASP) 237
TABLE 244 MIDDLE EAST AND AFRICA VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 237
TABLE 245 MIDDLE EAST AND AFRICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS) 238
TABLE 246 MIDDLE EAST AND AFRICA BRANDED TYPES ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (ASP) 238
TABLE 247 MIDDLE EAST AND AFRICA ANTHRAX TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 238
TABLE 248 MIDDLE EAST AND AFRICA ANTHRAX TREATMENT MARKET, BY END USERS, 2020-2029 (USD MILLION) 238
TABLE 249 SOUTH AFRICA ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 239
TABLE 250 SOUTH AFRICA CUTANEOUS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 239
TABLE 251 SOUTH AFRICA ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 239
TABLE 252 SOUTH AFRICA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 239
TABLE 253 SOUTH AFRICA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS) 240